# Oral chemotherapy versus intravenous chemotherapy in limited or extensive small cell lung cancer

Submission date	Recruitment status Stopped	☐ Prospectively registered		
01/07/2001		☐ Protocol		
Registration date	Overall study status Stopped Condition category	Statistical analysis plan		
01/07/2001		☐ Results		
Last Edited		Individual participant data		
18/09/2017	Cancer	Record updated in last year		

#### Plain English summary of protocol

Not provided at time of registration

#### Contact information

#### Type(s)

Scientific

#### Contact name

Dr - -

#### Contact details

UKCCCR Register Co-ordinator MRC Clinical Trials Unit 222 Euston Road London United Kingdom NW1 2DA

#### Additional identifiers

Protocol serial number

LU309

# Study information

#### Scientific Title

Oral chemotherapy versus intravenous chemotherapy in limited or extensive small cell lung cancer: a randomised controlled trial

#### **Study objectives**

Not provided at time of registration

#### Ethics approval required

Old ethics approval format

#### Ethics approval(s)

Not provided at time of registration

#### Study design

Randomised controlled trial

#### Primary study design

Interventional

#### Study type(s)

#### Health condition(s) or problem(s) studied

Lung (small cell)

#### **Interventions**

- 1. Oral Regimen: Oral etoposide and cyclophosphamide given over 5 days every 3 weeks.
- 2. Intravenous Regimen: Intravenous combination of three or more drugs routinely used in the centre with the usual dose reduction. A standard alternative is adriamycin, cyclophosphamide and vincristine (VAC) repeated every 3 weeks.

#### Intervention Type

Other

#### Phase

**Not Specified** 

#### Primary outcome(s)

Not provided at time of registration

#### Key secondary outcome(s))

Not provided at time of registration

#### Completion date

31/12/2000

#### Reason abandoned (if study stopped)

Objectives no longer viable

## **Eligibility**

#### Key inclusion criteria

- 1. Histologically or cytologically proven small cell lung cancer
- 2. No previous or concurrent malignancy
- 3. Fit to receive chemotherapy

- 4. No prior chemotherapy or radiotherapy
- 5. No biochemical or haematological abnormalities which would preclude chemotherapy

#### Participant type(s)

**Patient** 

#### Healthy volunteers allowed

No

#### Age group

**Not Specified** 

Sex

#### Key exclusion criteria

Not provided at time of registration

#### Date of first enrolment

01/01/1995

#### Date of final enrolment

31/12/2000

#### Locations

#### Countries of recruitment

**United Kingdom** 

England

# Study participating centre UKCCCR Register Co-ordinator

London United Kingdom NW1 2DA

# Sponsor information

#### Organisation

Cancer Research UK (CRUK) (UK)

#### **ROR**

https://ror.org/054225q67

# Funder(s)

#### Funder type

Charity

#### Funder Name

Cancer Research UK

#### Alternative Name(s)

CR\_UK, Cancer Research UK - London, Cancer Research UK (CRUK), CRUK

#### **Funding Body Type**

Private sector organisation

#### **Funding Body Subtype**

Other non-profit organizations

#### Location

**United Kingdom** 

### **Results and Publications**

Individual participant data (IPD) sharing plan

#### IPD sharing plan summary

#### **Study outputs**

Output type	Details	Date created Date added	Peer reviewed?	Patient-facing?
Interim results article	interim results	31/08/1996	Yes	No
Participant information sheet	Participant information sheet	11/11/2025 11/11/2025	No	Yes